NCT06080074 Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
| NCT ID | NCT06080074 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Stanford University |
| Condition | Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-04-15 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 50 participants in total. It began in 2025-04-15 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
There are two primary goals of this multicenter clinical trial that combines an FDA device trial and a phase II drug trial in the same study cohort. These two goals are to: 1. To evaluate the safety and effectiveness of the Cardiohelp Device for VA-ECMO (heart-lung support) for up to 30 days of support in children with severe heart failure with the goal to support its FDA clearance in children. 2. To evaluate heparin versus bivalirudin as the primary blood thinner (anticoagulant) in a randomized trial of children supported with the Cardiohelp ECMO System with the goal to plan a phase III (pivotal) randomized clinical trial The main questions the Cardiohelp single-arm trial seeks to answer are: * What is the safety and effectiveness of the Cardiohelp device for pediatric ECMO? * Should the Cardiohelp device be FDA-cleared for children based on the results of the study? * What are the optimal performance specifications of the Cardiohelp device in children? The main questions the blood thinner randomized trial seeks to answer are: * Which blood thinner is more promising (i.e., more effective and safer) in children on the Cardiohelp device? * How should a pivotal trial of heparin vs. bivalirudin be designed so it is the most informative and efficient to determine the best blood thinner? Children who are receiving the Cardiohelp device will be approached and consented to participate if interested. For the Cardiohelp device trial, participants will undergo a standardized data collection to estimate survival to 30 days and the prevalence of serious adverse events like stroke, bleeding, and hemolysis. For the blood thinner randomized trial, participants will be randomized 1:1 to blood thinner strategy to determine which blood thinner has the fewest bleeding and clotting complications. For the Cardiohelp single-arm trial, participant outcomes will be compared to performance goals (PG) derived from the ECMO literature. For the blood thinner randomized trial, the amount of bleeding and clotting will be measured. The study is funded by an R01 grant from the FDA's Office of Orphan Product Development (OOPD).
Eligibility Criteria
Inclusion Criteria: 1. Age 0 to 16 years of age (i.e., \<17 years) 2. Body weight 3 to 80 kilograms 3. VA-ECMO use for primary cardiac failure using the Cardiohelp system. 4. First ECMO run during the current hospitalization Exclusion Criteria:Children must not meet any of the following exclusion criteria within 48 hours prior to device implant: 1. Gestationally-corrected age \<37 weeks 2. Bleeding or coagulopathy that is a contraindication to anticoagulation 3. Irreversible renal, hepatic or lung failure 4. Stroke or uncertain neurological status within the past 30 days 5. Severely malnourished 6. Use of an ECMO system other than the Cardiohelp 7. VV-ECMO or ECMO for primary respiratory failure 8. Goals of patient to focus on comfort measures only. 9. Failure to separate from cardiopulmonary bypass 10. Allergy or contraindication to receiving UFH or bivalirudin as a primary anticoagulant on ECMO. 11. Patients who are pregnant or breastfeeding. 12. Unable to undergo randomization within 30 hours following ECMO cannulation (randomized cohort only)
Contact & Investigator
Lynn Sleeper, ScD
PRINCIPAL INVESTIGATOR
Boston Children's Hospital
Frequently Asked Questions
Who can join the NCT06080074 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 16 Years, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06080074 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06080074 currently recruiting?
Yes, NCT06080074 is actively recruiting participants. Contact the research team at calmond@stanford.edu for enrollment information.
Where is the NCT06080074 trial being conducted?
This trial is being conducted at Palo Alto, United States, New York, United States, Durham, United States, Dallas, United States and 1 additional location.
Who is sponsoring the NCT06080074 clinical trial?
NCT06080074 is sponsored by Stanford University. The principal investigator is Lynn Sleeper, ScD at Boston Children's Hospital. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.